These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20934459)

  • 1. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.
    Torresi J; McCarthy K; Feroldi E; Méric C
    Vaccine; 2010 Nov; 28(50):7993-8000. PubMed ID: 20934459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
    Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
    Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
    Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.
    Nasveld PE; Ebringer A; Elmes N; Bennett S; Yoksan S; Aaskov J; McCarthy K; Kanesa-thasan N; Meric C; Reid M
    Hum Vaccin; 2010 Dec; 6(12):1038-46. PubMed ID: 21150279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Appaiahgari MB; Vrati S
    Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
    Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
    Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
    Lyons A; Kanesa-thasan N; Kuschner RA; Eckels KH; Putnak R; Sun W; Burge R; Towle AC; Wilson P; Tauber E; Vaughn DW
    Vaccine; 2007 Apr; 25(17):3445-53. PubMed ID: 17241714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
    Huang LM; Lin TY; Chiu CH; Chiu NC; Chen PY; Yeh SJ; Boaz M; Hutagalung Y; Bouckenooghe A; Feroldi E
    Vaccine; 2014 Sep; 32(41):5363-9. PubMed ID: 24631095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.